查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1813251

2032 年左心耳封堵器市場預測：按產品類型、程序、材料成分、銷售管道、最終用戶和地區進行的全球分析

Left Atrial Appendage Closure Devices Market Forecasts to 2032 - Global Analysis By Product Type, Procedure, Material Composition, Sales Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球左心耳封堵器市場預計在 2025 年達到 22.2113 億美元，到 2032 年將達到 91.9449 億美元，預測期內的複合年成長率為 22.5%。

左心耳封堵器 (LAAC) 是一種用於降低無法耐受長期抗凝血藥物的心房顫動患者中風風險的植入。左心耳封堵器的作用原理是封閉左心耳（心臟中容易形成血栓的小腔體）。透過阻止血栓形成並進入血液循環，LAAC 為持續使用血液稀釋藥物提供了一種微創且可靠的替代方案。

心房顫動增加

全球心房顫動 (AF) 發病率的上升顯著增加了對左心耳封堵器 (LAAC) 的需求。由於 AF 是中風的主要原因，醫療保健系統優先考慮先進的預防干涉措施。 OPTION 等臨床試驗已證實，與長期抗凝血治療相比，LAAC 裝置在降低中風風險方面的有效性。全球人口老化，加上診斷能力的提升，正在擴大目標患者群。諸如新一代鎳鈦合金封堵器和聚合物塗層表面等技術進步，正在提高手術安全性和長期療效。這些因素共同推動了 LAAC 裝置在已開發市場和新興市場的持續普及。

設備相關併發症的風險

血栓症、心包膜儲存和手術漏等器械相關風險需要謹慎的患者選擇和操作人員的專業技能。新的設計旨在最大限度地減少這些問題，但術後監測和抗凝血方案仍然增加了複雜性。監管機構要求提供更長期的安全數據，這可能會延遲某些地區的產品核可。醫院必須投資專業培訓和影像技術才能獲得最佳療效，但這會導致護理成本增加。這些安全和營運挑戰持續阻礙市場擴張。

透過技術創新提高安全性和有效性

器械設計和輸送系統的快速技術創新為左心耳封堵術 (LAAC) 市場開闢了新的成長途徑。新產品採用增強的密封機制、較小的外形尺寸和生物可吸收材料，以降低併發症發生率。 3D 經食道和心內超音波心動圖等先進影像技術的整合，正在提高手術的準確性。在美國等市場，結合左心耳封堵術 (LAAC) 與心導管電氣燒灼術的混合療法正受到青睞，並受到優惠報銷代碼的支持。各公司也正在投資人工智慧主導的手術規劃工具，以最佳化患者治療效果。這些進步使左心耳封堵術 (LAAC) 更安全、更快捷，並讓更廣泛的患者群體更容易接受。

主要參與者之間的激烈競爭

左心耳封堵器市場主要製造商之間的激烈競爭為成長帶來了巨大的挑戰。現有參與者競相透過先進技術、臨床證據和產品創新來脫穎而出，這往往導致產品迭代周期加快和研發費用高昂。這種競爭壓力擠壓了利潤率，增加了行銷成本，並加速了產品淘汰。此外，激進的定價策略和重疊的產品系列使新參與企業難以獲得發展動力。隨著各公司爭奪市場佔有率，維持長期盈利極具挑戰性，尤其是在監管要求嚴格且滲透率較低的地區。

COVID-19的影響

新冠疫情最初擾亂了左心耳封堵術（LAAC），原因是擇期手術延後，醫院資源緊張。供應鏈中斷和患者就診減少減緩了設備的初步應用。然而，這場危機加速了向微創、更短療程、符合左心耳封堵術（LAAC）手術特徵的治療轉變。遠端醫療追蹤和遠端患者監護變得更加普遍，支持了醫療的連續性。最終，這場疫情強化了左心耳封堵術（LAAC）設備作為以患者為中心的、有韌性的心臟護理途徑的一部分的價值。

預計心內膜封堵器市場在預測期內將佔據最大佔有率

心內膜封堵器細分市場預計將在預測期內佔據最大市場佔有率，這得益於其微創特性和良好的臨床記錄。這些器械通常透過經導管途徑植入，與外科手術相比，可縮短住院時間和恢復時間。持續的設計改進，例如強化錨定系統和更柔順的框架，正在提高手術的成功率。堅實的臨床證據和主要市場不斷擴大的報銷範圍，支持了心內膜封堵器的廣泛應用。培訓計畫和基於模擬的教育正在提高操作人員的熟練程度，進一步推動其廣泛應用。隨著患者和醫生的偏好轉向更微創的解決方案，心內膜封堵器仍然是一個領先的產品類型。

預計門診手術中心部分在預測期內的複合年成長率最高

由於成本效益和患者便利性，預計門診手術中心細分市場將在預測期內實現最高成長率。器械輸送系統和影像引導技術的進步使當天出院越來越可行。門診手術中心 (ASC) 具有簡化工作流程、降低營運成本和提高患者周轉率等優勢，對付款人和醫療保健提供者都具有吸引力。多個國家/地區的優惠報銷政策進一步推動了向門診介入心臟病學的轉變。器械製造商與 ASC 網路之間的合作正在擴大社區環境中左心耳封鎖 (LAAC) 技術的應用。隨著微創技術的不斷發展，這一趨勢預計將加速發展。

比最大的地區

預計亞太地區將在預測期內佔據最大的市場佔有率，這得益於心房顫動患者的快速成長和醫療保健投資的增加。中國、日本和印度等國家正在透過公共和私人舉措擴大獲得先進心臟干預的機會。由於擁有熟練的介入性心臟病專家，微創心臟病學手術的應用日益廣泛。政府支持醫療基礎設施現代化的計畫正在提高手術能力。本地製造夥伴關係有助於降低設備成本並提高供給能力。強勁的需求基本面和不斷擴大的手術能力可能使亞太地區成為左心耳封堵器市場的重點區域。

複合年成長率最高的地區

預計北美地區在預測期內將呈現最高的複合年成長率，這得益於其早期採用的尖端左心房封堵技術以及健全的報銷框架。該地區心房顫動盛行率高，並受益於成熟的心臟護理網路和強大的臨床研究活動。持續的產品創新，例如下一代封堵器和人工智慧輔助的手術規劃，正在加速其應用。 FDA 等機構的監管明確性，使新設備更快進入市場。醫生培訓計畫和病患意識提升宣傳活動也進一步推動了其應用。

免費客製化服務

此報告的訂閱者可以使用以下免費自訂選項之一：

  • 公司簡介
    • 全面分析其他市場參與者（最多 3 家公司）
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球左心耳封堵器市場（依產品類型）

  • 心內膜封堵器
    • Watchman 設備系列
    • LAmbre 裝置
    • Amplatzer Amulet
  • 心外膜封堵器
    • LARIAT縫合線輸送裝置
    • AtriClip
  • 輸送/接入系統和鞘套

6. 全球左心耳封堵器市場（依手術方式）

  • 經導管入路
  • 微創手術方法
  • 混合

7. 全球左心耳封堵器市場（依材料成分）

  • 鎳鈦合金基裝置
  • 聚合物塗層
  • 不銹鋼及合金

8. 全球左心耳封堵器市場（依銷售管道）

  • 直銷
  • 批發商

9. 全球左心耳封堵器市場（依最終用戶）

  • 三級醫療機構
  • 門診手術中心（ASC）
  • 專門的心臟中心
  • 其他

10. 全球左心耳封堵器市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司概況

  • Abbott Laboratories
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • Boston Scientific Corporation
  • Occlufit Medical Ltd.
  • Johnson & Johnson
  • EpiCardia Technologies, Inc.
  • AtriCure, Inc.
  • WL Gore & Associates, Inc.
  • Lifetech Scientific Corporation
  • Keystone Heart Ltd.
  • Occlutech Holding AG
  • SMT
  • Acutus Medical, Inc.
  • MicroPort Scientific Corporation
  • Cardia, Inc.
Product Code: SMRC30710

According to Stratistics MRC, the Global Left Atrial Appendage Closure Devices Market is accounted for $2221.13 million in 2025 and is expected to reach $9194.49 million by 2032 growing at a CAGR of 22.5% during the forecast period. Left Atrial Appendage Closure (LAAC) devices are implants used to lower stroke risk in individuals with atrial fibrillation who cannot tolerate long-term anticoagulant drugs. They function by closing off the left atrial appendage, a small chamber in the heart where clots often develop. By blocking clot formation from entering circulation, LAAC devices serve as a minimally invasive and reliable alternative to continuous use of blood-thinning medications.

Market Dynamics:

Driver:

Rising prevalence of atrial fibrillation

The growing incidence of atrial fibrillation (AF) worldwide is significantly increasing the demand for left atrial appendage closure (LAAC) devices. As AF is a leading cause of stroke, healthcare systems are prioritizing advanced preventive interventions. Clinical trials, such as the OPTION study, have reinforced the efficacy of LAAC devices in reducing stroke risk compared to long-term anticoagulation. The aging global population, coupled with improved diagnostic capabilities, is expanding the eligible patient pool. Technological advancements, including next-generation nitinol-based occludes and polymer-coated surfaces, are enhancing procedural safety and long-term outcomes. Together, these factors are driving sustained adoption of LAAC devices across both developed and emerging healthcare markets.

Restraint:

Risk of device-related complications

Risks such as device-related thrombosis, pericardial effusion, and procedural leaks require careful patient selection and operator expertise. While newer designs aim to minimize these issues, post-procedural monitoring and anticoagulation protocols still add complexity. Regulatory bodies are demanding more long-term safety data, which can slow product approvals in certain regions. Hospitals must invest in specialized training and imaging technologies to ensure optimal outcomes, increasing procedural costs. These safety and operational challenges continue to temper the pace of market expansion.

Opportunity:

Technological innovations improving safety and efficacy

Rapid innovation in device design and delivery systems is opening new growth avenues for the LAAC market. Emerging products feature enhanced sealing mechanisms, reduced profile sizes, and bioresorbable materials to lower complication rates. Integration of advanced imaging modalities, such as 3D transesophageal echocardiography and intracardiac echocardiography, is improving procedural precision. Hybrid approaches that combine LAAC with catheter ablation are gaining traction, supported by favorable reimbursement codes in markets like the U.S. Companies are also investing in AI-driven procedural planning tools to optimize patient outcomes. These advancements are making LAAC procedures safer, faster, and more accessible to a wider patient base.

Threat:

Intense competition among key players

Fierce rivalry among leading manufacturers in the Left Atrial Appendage Closure Devices market is creating significant challenges for growth. Established players are locked in a race to differentiate through advanced technology, clinical evidence, and product innovation, often leading to rapid iteration cycles and high R&D spending. This competitive pressure compresses profit margins, intensifies marketing costs, and accelerates product obsolescence. Additionally, aggressive pricing strategies and overlapping product portfolios make it harder for new entrants to gain traction. As companies vie for market share, sustaining long-term profitability becomes difficult, especially in regions with stringent regulatory requirements and slower adoption rates.

Covid-19 Impact

The COVID-19 pandemic initially disrupted LAAC procedures due to postponed elective surgeries and strained hospital resources. Supply chain interruptions and reduced patient visits slowed device adoption in early phases. However, the crisis also accelerated the shift toward minimally invasive, short-stay interventions, aligning with LAAC's procedural profile. Telemedicine follow-ups and remote patient monitoring became more common, supporting continuity of care. The pandemic ultimately reinforced the value of LAAC devices as part of resilient, patient-centered cardiac care pathways.

The endocardial closure devices segment is expected to be the largest during the forecast period

The endocardial closure devices segment is expected to account for the largest market share during the forecast period, due to their minimally invasive nature and strong clinical track record. These devices, often delivered via transcatheter approaches, reduce hospital stays and recovery times compared to surgical alternatives. Continuous design improvements, such as enhanced anchoring systems and conformable frames, are boosting procedural success rates. Widespread adoption is supported by robust clinical evidence and expanding reimbursement coverage in key markets. Training programs and simulation-based education are increasing operator proficiency, further driving uptake. As patient and physician preference shifts toward less invasive solutions, endocardial devices will remain the leading product category.

The ambulatory surgical centers segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the ambulatory surgical centers segment is predicted to witness the highest growth rate, due to their cost efficiency and patient convenience. Advances in device delivery systems and imaging guidance have made same-day discharge increasingly feasible. ASCs benefit from streamlined workflows, lower overhead costs, and high patient turnover, making them attractive for payers and providers. The shift toward outpatient cardiac interventions is being reinforced by favourable reimbursement policies in several countries. Partnerships between device manufacturers and ASC networks are expanding access to LAAC technology in community settings. This trend is set to accelerate as minimally invasive techniques continue to evolve.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share driven by a rapidly growing patient base with atrial fibrillation and rising healthcare investments. Countries like China, Japan, and India are expanding access to advanced cardiac interventions through public and private initiatives. Increasing adoption of minimally invasive cardiology procedures is supported by the availability of skilled interventional cardiologists. Government-backed programs to modernize healthcare infrastructure are improving procedural capacity. Local manufacturing partnerships are helping reduce device costs and improve availability. With strong demand fundamentals and expanding procedural capabilities, Asia Pacific will remain the anchor region for LAAC market.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, fuelled by early adoption of cutting-edge LAAC technologies and robust reimbursement frameworks. The region benefits from a high prevalence of atrial fibrillation, well-established cardiac care networks, and strong clinical research activity. Continuous product innovation, including next-generation occludes and AI-assisted procedural planning, is accelerating uptake. Regulatory clarity from agencies like the FDA is enabling faster market entry for new devices. Physician training programs and patient awareness campaigns are further boosting adoption rates.

Key players in the market

Some of the key players profiled in the Left Atrial Appendage Closure Devices Market include Abbott Laboratories, Lepu Medical Technology (Beijing) Co., Ltd., Boston Scientific Corporation, Occlufit Medical Ltd., Johnson & Johnson, EpiCardia Technologies, Inc., AtriCure, Inc., W. L. Gore & Associates, Inc., Lifetech Scientific Corporation, Keystone Heart Ltd., Occlutech Holding AG, SMT, Acutus Medical, Inc., MicroPort Scientific Corporation, and Cardia, Inc.

Key Developments:

In July 2025, Johnson & Johnson MedTech announced the launch of the VIRTUGUIDE(TM) System. This AI-powered, patient-matched solution is designed to support Lapidus procedures2, a type of bunion surgery that helps realign the foot by joining two bones near the arch. The system uses pre-operative planning software, developed in collaboration with PeekMed(R), to assess each patient's bunion and make personalized recommendations for the intended correction.

In April 2025, Abbott announced the launch of its neuromodulation business' next-generation delivery system, which will be used to streamline the implantation process for electrodes used as part of its Proclaim(TM) DRG neurostimulation system. The new system is intended to streamline the procedure when doctors implant the system in patients who are suffering from complex regional pain syndrome (CRPS) Type 1 and causalgia (CRPS Type 2) of the lower extremities.

Product Types Covered:

  • Endocardial Closure Devices
  • Epicardial Closure Devices
  • Delivery/Access Systems & Sheaths

Procedures Covered:

  • Transcatheter Approach
  • Minimally Invasive Surgical Approach
  • Hybrid

Material Compositions Covered:

  • Nitinol-Based Devices
  • Polymer-Coated
  • Stainless Steel & Alloys

Sales Channels Covered:

  • Direct Sales
  • Distributor

End Users Covered:

  • Tertiary Care Hospitals
  • Ambulatory Surgical Centers (ASCs)
  • Specialty Cardiac Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Left Atrial Appendage Closure Devices Market, By Product Type

  • 5.1 Introduction
  • 5.2 Endocardial Closure Devices
    • 5.2.1 Watchman Device Family
    • 5.2.2 LAmbre Device
    • 5.2.3 Amplatzer Amulet
  • 5.3 Epicardial Closure Devices
    • 5.3.1 LARIAT Suture Delivery Device
    • 5.3.2 AtriClip
  • 5.4 Delivery/Access Systems & Sheaths

6 Global Left Atrial Appendage Closure Devices Market, By Procedure

  • 6.1 Introduction
  • 6.2 Transcatheter Approach
  • 6.3 Minimally Invasive Surgical Approach
  • 6.4 Hybrid

7 Global Left Atrial Appendage Closure Devices Market, By Material Composition

  • 7.1 Introduction
  • 7.2 Nitinol-Based Devices
  • 7.3 Polymer-Coated
  • 7.4 Stainless Steel & Alloys

8 Global Left Atrial Appendage Closure Devices Market, By Sales Channel

  • 8.1 Introduction
  • 8.2 Direct Sales
  • 8.3 Distributor

9 Global Left Atrial Appendage Closure Devices Market, By End User

  • 9.1 Introduction
  • 9.2 Tertiary Care Hospitals
  • 9.3 Ambulatory Surgical Centers (ASCs)
  • 9.4 Specialty Cardiac Centers
  • 9.5 Other End Users

10 Global Left Atrial Appendage Closure Devices Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Abbott Laboratories
  • 12.2 Lepu Medical Technology (Beijing) Co., Ltd.
  • 12.3 Boston Scientific Corporation
  • 12.4 Occlufit Medical Ltd.
  • 12.5 Johnson & Johnson
  • 12.6 EpiCardia Technologies, Inc.
  • 12.7 AtriCure, Inc.
  • 12.8 W. L. Gore & Associates, Inc.
  • 12.9 Lifetech Scientific Corporation
  • 12.10 Keystone Heart Ltd.
  • 12.11 Occlutech Holding AG
  • 12.12 SMT
  • 12.13 Acutus Medical, Inc.
  • 12.14 MicroPort Scientific Corporation
  • 12.15 Cardia, Inc.

List of Tables

  • Table 1 Global Left Atrial Appendage Closure Devices Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Left Atrial Appendage Closure Devices Market Outlook, By Product Type (2024-2032) ($MN)
  • Table 3 Global Left Atrial Appendage Closure Devices Market Outlook, By Endocardial Closure Devices (2024-2032) ($MN)
  • Table 4 Global Left Atrial Appendage Closure Devices Market Outlook, By Watchman Device Family (2024-2032) ($MN)
  • Table 5 Global Left Atrial Appendage Closure Devices Market Outlook, By LAmbre Device (2024-2032) ($MN)
  • Table 6 Global Left Atrial Appendage Closure Devices Market Outlook, By Amplatzer Amulet (2024-2032) ($MN)
  • Table 7 Global Left Atrial Appendage Closure Devices Market Outlook, By Epicardial Closure Devices (2024-2032) ($MN)
  • Table 8 Global Left Atrial Appendage Closure Devices Market Outlook, By LARIAT Suture Delivery Device (2024-2032) ($MN)
  • Table 9 Global Left Atrial Appendage Closure Devices Market Outlook, By AtriClip (2024-2032) ($MN)
  • Table 10 Global Left Atrial Appendage Closure Devices Market Outlook, By Delivery/Access Systems & Sheaths (2024-2032) ($MN)
  • Table 11 Global Left Atrial Appendage Closure Devices Market Outlook, By Procedure (2024-2032) ($MN)
  • Table 12 Global Left Atrial Appendage Closure Devices Market Outlook, By Transcatheter Approach (2024-2032) ($MN)
  • Table 13 Global Left Atrial Appendage Closure Devices Market Outlook, By Minimally Invasive Surgical Approach (2024-2032) ($MN)
  • Table 14 Global Left Atrial Appendage Closure Devices Market Outlook, By Hybrid (2024-2032) ($MN)
  • Table 15 Global Left Atrial Appendage Closure Devices Market Outlook, By Material Composition (2024-2032) ($MN)
  • Table 16 Global Left Atrial Appendage Closure Devices Market Outlook, By Nitinol-Based Devices (2024-2032) ($MN)
  • Table 17 Global Left Atrial Appendage Closure Devices Market Outlook, By Polymer-Coated (2024-2032) ($MN)
  • Table 18 Global Left Atrial Appendage Closure Devices Market Outlook, By Stainless Steel & Alloys (2024-2032) ($MN)
  • Table 19 Global Left Atrial Appendage Closure Devices Market Outlook, By Sales Channel (2024-2032) ($MN)
  • Table 20 Global Left Atrial Appendage Closure Devices Market Outlook, By Direct Sales (2024-2032) ($MN)
  • Table 21 Global Left Atrial Appendage Closure Devices Market Outlook, By Distributor (2024-2032) ($MN)
  • Table 22 Global Left Atrial Appendage Closure Devices Market Outlook, By End User (2024-2032) ($MN)
  • Table 23 Global Left Atrial Appendage Closure Devices Market Outlook, By Tertiary Care Hospitals (2024-2032) ($MN)
  • Table 24 Global Left Atrial Appendage Closure Devices Market Outlook, By Ambulatory Surgical Centers (ASCs) (2024-2032) ($MN)
  • Table 25 Global Left Atrial Appendage Closure Devices Market Outlook, By Specialty Cardiac Centers (2024-2032) ($MN)
  • Table 26 Global Left Atrial Appendage Closure Devices Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.